p53 antibody

Catalog No. ABIN967421

The Mouse Monoclonal anti-p53 antibody has been validated for WB, IF, IHC (p), IP and IHC (fro). It is suitable to detect p53 in samples from Human. There are 8+ publications available.

Quick Overview for p53 antibody (ABIN967421)

Target: p53 (TP53) (Tumor Protein P53 (TP53))

Reactivity: Human

Host: Mouse

Clonality: Monoclonal

Conjugate: This p53 antibody is un-conjugated

Application: Western Blotting (WB), Immunofluorescence (IF), Immunohistochemistry (Paraffin-embedded Sections) (IHC (p)), Immunoprecipitation (IP), Immunohistochemistry (Frozen Sections) (IHC (fro))

Clone: PAb 1801

Product Details anti-p53 Antibody

Brand: BD Pharmingen™

Characteristics: 1. Since applications vary, each investigator should titrate the reagent to obtain optimal results.
2. Please refer to us for technical protocols.
3. Caution: Sodium azide yields highly toxic hydrazoic acid under acidic conditions. Dilute azide compounds in running water before discarding to avoid accumulation of potentially explosive deposits in plumbing.

Purification: The monoclonal antibody was purified from tissue culture supernatant or ascites by affinity chromatography.

Immunogen: Recombinant fusion protein

Isotype: IgG1

Application Details

Application Notes: Applications include western blot analysis (1-2 µg/ml), immunoprecipitation (1-2 µg/1 x 10^6 cells), immunofluorescence microscopy of cultured cells, immunohistochemistry of frozen (5-20 µg/ml), and antigen-unmasked paraffin-embedded tissue sections (5-20 µg/ml). Positive control cell lines include SK-BR-3 human breast carcinoma cells (ATCC HTB-30), and A431 human vulval carcinoma cells (ATCC CRL-1555). COS-7 SV40 transformed monkey kidney cells (ATCC CRL-1651) or another SV40-transformed cell line are also useful as positive controls for detecting p53. MCF-7 human breast carcinoma cells (ATCC HTB-22) are suggested as a negative control. Positive immunostaining is seen in a high proportion of breast and colon carcinomas. p53 staining is not typically detected in normal skin, brain, kidney, lung, stomach or breast tissue.

Restrictions: For Research Use only

Handling

Format: Liquid

Concentration: 0.5 mg/mL

Buffer: Aqueous buffered solution containing ≤0.09 % sodium azide.

Preservative: Sodium azide

Precaution of Use: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Storage: 4 °C

Storage Comment: Store undiluted at 4°C.

References for anti-p53 antibody (ABIN967421)

Jacquemier, Molès, Penault-Llorca, Adélaide, Torrente, Viens, Birnbaum, Theillet: "p53 immunohistochemical analysis in breast cancer with four monoclonal antibodies: comparison of staining and PCR-SSCP results." in: British journal of cancer, Vol. 69, Issue 5, pp. 846-52, (1994) (PubMed).

Legros, Lacabanne, dAgay, Larsen, Pla, Soussi: "Production of human p53 specific monoclonal antibodies and their use in immunohistochemical studies of tumor cells." in: Bulletin du cancer, Vol. 80, Issue 2, pp. 102-10, (1994) (PubMed).

Said, Barrera, Shintaku, Nakamura, Koeffler: "Immunohistochemical analysis of p53 expression in malignant lymphomas." in: The American journal of pathology, Vol. 141, Issue 6, pp. 1343-8, (1993) (PubMed).

Vojt?sek, Bártek, Midgley, Lane: "An immunochemical analysis of the human nuclear phosphoprotein p53. New monoclonal antibodies and epitope mapping using recombinant p53." in: Journal of immunological methods, Vol. 151, Issue 1-2, pp. 237-44, (1992) (PubMed).

Walker, Dearing, Lane, Varley: "Expression of p53 protein in infiltrating and in-situ breast carcinomas." in: The Journal of pathology, Vol. 165, Issue 3, pp. 203-11, (1992) (PubMed).

Vogelstein: "Cancer. A deadly inheritance." in: Nature, Vol. 348, Issue 6303, pp. 681-2, (1991) (PubMed).

Baker, Markowitz, Fearon, Willson, Vogelstein: "Suppression of human colorectal carcinoma cell growth by wild-type p53." in: Science (New York, N.Y.), Vol. 249, Issue 4971, pp. 912-5, (1990) (PubMed).

Banks, Matlashewski, Crawford: "Isolation of human-p53-specific monoclonal antibodies and their use in the studies of human p53 expression." in: European journal of biochemistry / FEBS, Vol. 159, Issue 3, pp. 529-34, (1986) (PubMed).

Target Details for p53

Target: p53 (TP53) (Tumor Protein P53 (TP53))

Alternative Name: p53

Background: The gene for the nuclear phosphoprotein p53 is the most commonly mutated gene yet identified in human cancers. Missense mutations occur in tumors of the colon, lung, breast, ovary, bladder and several other organs. The mutant p53 is over-expressed in a variety of transformed cells and it forms specific complexes with several viral oncogenes including SV40 large T, E1B from adenovirus and E6 from human papilloma virus. Recent data suggest that wild type p53 plays a role as a checkpoint protein for DNA damage during the S-phase of the cell cycle. However, it is still unclear whether point mutated forms of p53 are simple null mutants and/or dominant negatively acting proteins. p53 migrates at a reduced molecular weight of 53 kDa. Clone PAb 1801 recognizes an epitope between amino acids 32-79 in the N-terminal domain of human wild type and mutant p53 antibody. It does not cross-react with p53 from other species. A truncated recombinant human p53 fusion protein was used as immunogen.

Molecular Weight: 53 kDa

Pathways: p53 Signaling, MAPK Signaling, PI3K-Akt Signaling, Apoptosis, AMPK Signaling, Chromatin Binding, ER-Nucleus Signaling, Positive Regulation of Endopeptidase Activity, Hepatitis C, Protein targeting to Nucleus, Autophagy, Warburg Effect